A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibilityand safety of intratumoral injection with or without intramural injection in subjects withbladder cancer November 7, 2023
An Open-Label, Phase 1/1b Study of ORIC-944 in Patients with Metastatic Prostate Cancer November 7, 2023
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies November 7, 2023
Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 in Patients with Advanced or Metastatic Solid Tumors November 7, 2023
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer November 7, 2023
Phase 1/1b, Multicenter, Open-LabeL, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors November 7, 2023
A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants with Advanced Cancer November 7, 2023
A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase I Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants with HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors November 7, 2023
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation November 7, 2023
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors November 7, 2023